Design Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Design Therapeutics R&D Spending Growth & History (DSGN)
Design Therapeutics's r&d spending was $59.1M for fiscal 2025.
View full Design Therapeutics company overviewDesign Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $59.1M | $14.8M | +33.32% |
| 2024 | 2024-12-31 | $44.4M | −$12.7M | −22.28% |
| 2023 | 2023-12-31 | $57.1M | $8.4M | +17.38% |
| 2022 | 2022-12-31 | $48.6M | $23.8M | +96.19% |
| 2021 | 2021-12-31 | $24.8M | $18.7M | +308.88% |
| 2020 | 2020-12-31 | $6.1M | — | — |
Design Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.4M | $650,000 | +4.13% |
| Q1 2026 | 2026-03-31 | $14.4M | −$998,000 | −6.49% |
| Q4 2025 | 2025-12-31 | $13.4M | $1.3M | +10.43% |
| Q3 2025 | 2025-09-30 | $14.6M | $2.7M | +22.84% |
| Q2 2025 | 2025-06-30 | $15.7M | $5.2M | +49.66% |
| Q1 2025 | 2025-03-31 | $15.4M | $5.6M | +56.89% |
| Q4 2024 | 2024-12-31 | $12.2M | $1.1M | +10.40% |
| Q3 2024 | 2024-09-30 | $11.9M | −$1.4M | −10.42% |
| Q2 2024 | 2024-06-30 | $10.5M | −$6.5M | −38.37% |
| Q1 2024 | 2024-03-31 | $9.8M | −$5.9M | −37.69% |
| Q4 2023 | 2023-12-31 | $11.0M | −$3.2M | −22.75% |
| Q3 2023 | 2023-09-30 | $13.3M | −$1.0M | −7.32% |
| Q2 2023 | 2023-06-30 | $17.1M | $5.8M | +51.08% |
| Q1 2023 | 2023-03-31 | $15.7M | $7.0M | +79.59% |
| Q4 2022 | 2022-12-31 | $14.3M | $6.9M | +94.29% |
| Q3 2022 | 2022-09-30 | $14.3M | $5.8M | +67.51% |
| Q2 2022 | 2022-06-30 | $11.3M | $6.3M | +124.69% |
| Q1 2022 | 2022-03-31 | $8.8M | $4.9M | +126.04% |
| Q4 2021 | 2021-12-31 | $7.3M | $4.6M | +170.94% |
| Q3 2021 | 2021-09-30 | $8.5M | $6.6M | +346.13% |
| Q2 2021 | 2021-06-30 | $5.0M | $4.0M | +373.80% |
| Q1 2021 | 2021-03-31 | $3.9M | $3.5M | +927.85% |
| Q4 2020 | 2020-12-31 | $2.7M | — | — |
| Q3 2020 | 2020-09-30 | $1.9M | — | — |
| Q2 2020 | 2020-06-30 | $1.1M | — | — |
| Q1 2020 | 2020-03-31 | $377,000 | — | — |
Design Therapeutics r&d spending trends
Over the last five fiscal years, Design Therapeutics's r&d spending increased from $6.1M to $59.1M, a change of $53.1M. The latest reported quarter, Q2 2026, shows $16.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Design Therapeutics source filings ↗